Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-242 and G-CSF in sAH and ACLF
NCT06890039Phase 2Recruiting
- Sponsor
- Yaqrit
- Start
- Jun 2026
- Primary completion
- Aug 2028
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of resatorvid in acute-on-chronic liver failure (ACLF) and alcoholic hepatitis (AH) (3 arms), sponsored by Yaqrit. Primary endpoint: Safety of TAK-242 in combination with G-CSF and alone at Day 14. Started Jun 2026; status: recruiting.
02
Drugs
resatorvid
03
Conditions
acute-on-chronic liver failure (ACLF)alcoholic hepatitis (AH)
Beyond the preview
Go deeper on NCT06890039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06890039.